Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Liabilities and Shareholders Equity (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Liabilities and Shareholders Equity for 11 consecutive years, with $138.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 780.8% to $138.3 million in Q3 2025 year-over-year; TTM through Dec 2025 was $301.7 million, a N/A change, with the full-year FY2023 number at $45.3 million, down 12.53% from a year prior.
  • Liabilities and Shareholders Equity was $138.3 million for Q3 2025 at Crescent Biopharma, down from $157.4 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $157.4 million in Q2 2025 to a low of $6.0 million in Q1 2025.
  • A 5-year average of $73.6 million and a median of $63.4 million in 2022 define the central range for Liabilities and Shareholders Equity.
  • Biggest YoY gain for Liabilities and Shareholders Equity was 780.8% in 2025; the steepest drop was 82.48% in 2025.
  • Crescent Biopharma's Liabilities and Shareholders Equity stood at $94.3 million in 2021, then tumbled by 45.08% to $51.8 million in 2022, then dropped by 12.53% to $45.3 million in 2023, then plummeted by 65.36% to $15.7 million in 2024, then surged by 780.8% to $138.3 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Liabilities and Shareholders Equity are $138.3 million (Q3 2025), $157.4 million (Q2 2025), and $6.0 million (Q1 2025).